Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | FBXO25 | CTRPv2 | pan-cancer | AAC | 0.13 | 6e-05 |
mRNA | VWCE | CTRPv2 | pan-cancer | AAC | 0.14 | 6e-05 |
mRNA | CENPC | CTRPv2 | pan-cancer | AAC | 0.15 | 6e-05 |
mRNA | RP11-426L16.10 | CTRPv2 | pan-cancer | AAC | -0.16 | 6e-05 |
mRNA | CCSAP | CTRPv2 | pan-cancer | AAC | 0.13 | 6e-05 |
mRNA | VAMP3 | CTRPv2 | pan-cancer | AAC | -0.16 | 6e-05 |
mRNA | SUPT16H | CTRPv2 | pan-cancer | AAC | 0.13 | 6e-05 |
mRNA | UNC119B | CTRPv2 | pan-cancer | AAC | 0.13 | 6e-05 |
mRNA | CNTD2 | CTRPv2 | pan-cancer | AAC | 0.13 | 6e-05 |
mRNA | ZNF324 | CTRPv2 | pan-cancer | AAC | 0.14 | 6e-05 |